The EGFR-specific antibody cetuximab combined with chemotherapy triggers immunogenic cell death

The cancer therapeutic cetuximab blocks EGFR signaling on tumor cells. Pozzi et al. now show that this antibody, when combined with chemotherapy, can also kill colorectal cancer cells by triggering immunogenic cell death.